Breaking
Notable MedicineSTAT (INT)

STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say

Pharma companies that make GLP-1 drugs have increasingly promoted telehealth companies that prescribe the popular treatments. With a new deal announced this week, one of those relationships is expected to grow more complicated. Eli Lilly has been…

Read the full story at STAT ↗

ImpactNotable
Published14 h ago (Fri, 13 Nov 2026 09:30:00 GMT)
AuthorElaine Chen
MoreLess
Impact score41/100
RatingProbability of 43%.
RegionsGlobal
Retrievedvia rss
ClassifiedFri, 13 Nov 2026 10:37:12 GMT by classifier